Selcia has acquired the intellectual property and expertise of the CE Screen and adapted the technology for fragment screening.
The company has also unveiled its new brand, which reflects Selcia's expansion and growth plans and is accompanied by a redesigned website to better communicate its enhanced offering.
Selcia's Discovery operating division has been based around a technology adapted by Selcia to detect the weak binding interactions between fragments and the therapeutic target.
